Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Use of ivermectin in the treatment of Covid-19: a pilot trial

Pott-Junior et al., Toxicology Reports, doi:10.1016/j.toxrep.2021.03.003, NCT04431466
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ventilation 85% Improvement Relative Risk ICU admission 85% Improvement in Ct value 1% Viral clearance -11% primary Time to viral- 17% no CI Ivermectin  Pott-Junior et al.  LATE TREATMENT  RCT Is late treatment with ivermectin beneficial for COVID-19? RCT 31 patients in Brazil (July - December 2020) Lower ventilation (p=0.25) and ICU admission (p=0.25), not sig. c19ivm.org Pott-Junior et al., Toxicology Reports, Mar 2021 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Very small RCT with 4 control patients and 28 ivermectin patients split across 3 different dosage levels, showing lower (non-statistically significant) ICU admission with treatment. Authors suggest that ivermectin for SARS-CoV-2 is safe and reduces symptoms and viral load, and that the antiviral effect appears to be dose-dependent. NCT04431466 (history).
Retraction/censorship: this paper appears to have been censored at the request of the journal's founding editor1. An external review is mentioned but is not provided, and there is no reply from the authors, or indication that the authors were notified. Conclusions in this study are limited due to the small size, however we should consider all information in the context of the full body of research.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This is the 20th of 51 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000015.
This is the 42nd of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of mechanical ventilation, 85.2% lower, RR 0.15, p = 0.25, treatment 1 of 27 (3.7%), control 1 of 4 (25.0%), NNT 4.7.
risk of ICU admission, 85.2% lower, RR 0.15, p = 0.25, treatment 1 of 27 (3.7%), control 1 of 4 (25.0%), NNT 4.7.
relative improvement in Ct value, 0.8% better, RR 0.99, p = 1.00, treatment 27, control 3.
risk of no viral clearance, 11.1% higher, RR 1.11, p = 1.00, treatment 10 of 27 (37.0%), control 1 of 3 (33.3%), primary outcome.
time to viral-, 16.7% lower, relative time 0.83, treatment 27, control 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pott-Junior et al., 9 Mar 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 10 authors, study period 1 July, 2020 - 1 December, 2020, average treatment delay 8.0 days, dosage 200μg/kg single dose, dose varies in three arms 100, 200, 400μg/kg, trial NCT04431466 (history).
This PaperIvermectinAll
RETRACTED: Use of ivermectin in the treatment of Covid-19: A pilot trial
Henrique Pott-Junior, Mˆonica Maria Bastos Paoliello, Alice De Queiroz Constantino Miguel, Anderson Ferreira Da Cunha, Caio Cesar De Melo Freire, F´abio Fernandes Neves, Lucimar Retto Da Silva De Av´o, Meliza Goi Roscani, Sigrid De Sousa Dos Santos, Silvana Gama Florêncio Chach´a
Toxicology Reports, doi:10.1016/j.toxrep.2021.03.003
In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19. Methods: Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466). Results: A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests. Conclusions: Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.
CRediT authorship contribution statement Henrique Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.191
Alexandris, Lagoumintzis, Chasapis, Nicotinic cholinergic system and COVID-19: in silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions, Toxicol. Rep, doi:10.1016/j.toxrep.2020.12.013
Banerjee, Nandy, Dalai, Ahmed, The Battle against COVID 19 pandemic: what we need to know Before we "test fire" ivermectin, Drug Res. (Stuttg), doi:10.1055/a-1185-8913
Behera, Patro, Singh, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One, doi:10.1371/journal.pone.0247163
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Camprubi, Almuedo-Riera, Marti-Soler, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLoS One, doi:10.1371/journal.pone.0242184
Control, Prevention. CDC 2019-Novel Coronavirus (2019-Ncov) Real-Time RT-PCR Diagnostic Panel
Fajnzylber, Regan, Coxen, SARS-CoV-2 viral load is associated with increased disease severity and mortality, Nat. Commun, doi:10.1038/s41467-020-19057-5
Gonzalez Canga, Sahagun Prieto, Diez Liebana, Martinez, Sierra et al., The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
He, Lau, Wu, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat. Med, doi:10.1038/s41591-020-0869-5
Lagoumintzis, Chasapis, Alexandris, Nicotinic cholinergic system and COVID-19: in silico identification of interactions between alpha7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-v and SARS-CoV-2 spike glycoproteins, Food Chem. Toxicol, doi:10.1016/j.fct.2021.112009
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptorbinding domain attached to ACE2, Vivo, doi:10.21873/invivo.12134
Molento, COVID-19 and the rush for self-medication and self-dosing with ivermectin: a word of caution, One Health, doi:10.1016/j.onehlt.2020.100148
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis, J. Pharm. Pharm. Sci, doi:10.18433/jpps31457
Pena-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19, Br. J. Clin. Pharmacol, doi:10.1111/bcp.14476
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin Is associated with Lower mortality in hospitalized patients with coronavirus disease 2019: the ICON study, Chest, doi:10.1016/j.chest.2020.10.009
Sen Gupta, Biswal, Panda, Ray, Rana, Binding mechanism and structural insights into the identified protein target of COVID-19 and importinalpha with in-vitro effective drug ivermectin, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1839564
Siddiqui, Jahan, Ashraf, Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1802345
Telbisz, Ambrus, Mozner, Interactions of potential anti-COVID-19 compounds with multispecific ABC and OATP drug transporters, Pharmaceutics, doi:10.3390/pharmaceutics13010081
Walsh, Jordan, Clyne, SARS-CoV-2 detection, viral load and infectivity over the course of an infection, J. Infect, doi:10.1016/j.jinf.2020.06.067
Yan, Ci, Chen, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm. Res, doi:10.1007/s00011-011-0307-8
Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm. Res, doi:10.1007/s00011-008-8007-8
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T20:34:19Z', 'timestamp': 1712608459861}, 'update-to': [ { 'updated': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'DOI': '10.1016/j.toxrep.2021.03.003', 'type': 'retraction', 'label': 'Retraction'}], 'reference-count': 22, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 3, 8]], 'date-time': '2021-03-08T00:00:00Z', 'timestamp': 1615161600000}, 'content-version': 'vor', 'delay-in-days': 66, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021]]}, 'DOI': '10.1016/j.toxrep.2021.03.003', 'type': 'journal-article', 'created': {'date-parts': [[2021, 3, 10]], 'date-time': '2021-03-10T02:22:06Z', 'timestamp': 1615342926000}, 'page': '505-510', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 32, 'title': 'RETRACTED: Use of ivermectin in the treatment of Covid-19: A pilot trial', 'prefix': '10.1016', 'volume': '8', 'author': [ {'given': 'Henrique', 'family': 'Pott-Junior', 'sequence': 'first', 'affiliation': []}, { 'given': 'Mˆonica Maria Bastos', 'family': 'Paoliello', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Alice de Queiroz Constantino', 'family': 'Miguel', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Anderson Ferreira', 'family': 'da Cunha', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Caio Cesar', 'family': 'de Melo Freire', 'sequence': 'additional', 'affiliation': []}, {'given': 'F´abio Fernandes', 'family': 'Neves', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Lucimar Retto', 'family': 'da Silva de Av´o', 'sequence': 'additional', 'affiliation': []}, {'given': 'Meliza Goi', 'family': 'Roscani', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Sigrid De Sousa', 'family': 'dos Santos', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Silvana Gama Florêncio', 'family': 'Chach´a', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': 'August (8)', 'key': '10.1016/j.toxrep.2021.03.003_bib0005', 'first-page': '337', 'article-title': 'The Battle against COVID 19 pandemic: what we need to know Before we ' '"test fire" ivermectin', 'volume': '70', 'author': 'Banerjee', 'year': '2020', 'journal-title': 'Drug Res. (Stuttg)'}, { 'issue': 'September-October(5)', 'key': '10.1016/j.toxrep.2021.03.003_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '3023', 'DOI': '10.21873/invivo.12134', 'article-title': 'Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain ' 'attached to ACE2', 'volume': '34', 'author': 'Lehrer', 'year': '2020', 'journal-title': 'In Vivo'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0015', 'first-page': '1', 'article-title': 'Binding mechanism and structural insights into the identified protein ' 'target of COVID-19 and importin-alpha with in-vitro effective drug ' 'ivermectin', 'volume': '28', 'author': 'Sen Gupta', 'year': '2020', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1080/07391102.2020.1852117', 'article-title': 'Current status and strategic possibilities on potential use of ' 'combinational drug therapy against COVID-19 caused by SARS-CoV-2', 'volume': '5', 'author': 'Siddiqui', 'year': '2020', 'journal-title': 'J. Biomol. Struct. Dyn.'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0025', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0030', 'article-title': 'Pharmacokinetic considerations on the repurposing of ivermectin for ' 'treatment of COVID-19', 'volume': '17', 'author': 'Pena-Silva', 'year': '2020', 'journal-title': 'Br. J. Clin. Pharmacol.'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0035', 'series-title': 'Control C-CfD, Prevention. CDC 2019-Novel Coronavirus (2019-Ncov) ' 'Real-Time RT-PCR Diagnostic Panel', 'year': '2020'}, { 'issue': 'October (1)', 'key': '10.1016/j.toxrep.2021.03.003_bib0040', 'doi-asserted-by': 'crossref', 'first-page': '5493', 'DOI': '10.1038/s41467-020-19057-5', 'article-title': 'SARS-CoV-2 viral load is associated with increased disease severity and ' 'mortality', 'volume': '11', 'author': 'Fajnzylber', 'year': '2020', 'journal-title': 'Nat. Commun.'}, { 'issue': 'May(5)', 'key': '10.1016/j.toxrep.2021.03.003_bib0045', 'doi-asserted-by': 'crossref', 'first-page': '672', 'DOI': '10.1038/s41591-020-0869-5', 'article-title': 'Temporal dynamics in viral shedding and transmissibility of COVID-19', 'volume': '26', 'author': 'He', 'year': '2020', 'journal-title': 'Nat. Med.'}, { 'issue': 'September (3)', 'key': '10.1016/j.toxrep.2021.03.003_bib0050', 'doi-asserted-by': 'crossref', 'first-page': '357', 'DOI': '10.1016/j.jinf.2020.06.067', 'article-title': 'SARS-CoV-2 detection, viral load and infectivity over the course of an ' 'infection', 'volume': '81', 'author': 'Walsh', 'year': '2020', 'journal-title': 'J. Infect.'}, { 'issue': '1', 'key': '10.1016/j.toxrep.2021.03.003_bib0055', 'doi-asserted-by': 'crossref', 'first-page': '42', 'DOI': '10.1208/s12248-007-9000-9', 'article-title': 'The pharmacokinetics and interactions of ivermectin in humans--a ' 'mini-review', 'volume': '10', 'author': 'Gonzalez Canga', 'year': '2008', 'journal-title': 'AAPS J'}, { 'issue': 'January 9', 'key': '10.1016/j.toxrep.2021.03.003_bib0060', 'article-title': 'Interactions of potential anti-COVID-19 compounds with multispecific ' 'ABC and OATP drug transporters', 'volume': '13', 'author': 'Telbisz', 'year': '2021', 'journal-title': 'Pharmaceutics'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0065', 'doi-asserted-by': 'crossref', 'first-page': '73', 'DOI': '10.1016/j.toxrep.2020.12.013', 'article-title': 'Nicotinic cholinergic system and COVID-19: in silico evaluation of ' 'nicotinic acetylcholine receptor agonists as potential therapeutic ' 'interventions', 'volume': '8', 'author': 'Alexandris', 'year': '2021', 'journal-title': 'Toxicol. Rep.'}, { 'issue': 'January 24', 'key': '10.1016/j.toxrep.2021.03.003_bib0070', 'article-title': 'Nicotinic cholinergic system and COVID-19: in silico identification of ' 'interactions between alpha7 nicotinic acetylcholine receptor and the ' 'cryptic epitopes of SARS-Co-v and SARS-CoV-2 spike glycoproteins', 'volume': '149', 'author': 'Lagoumintzis', 'year': '2021', 'journal-title': 'Food Chem. Toxicol.'}, { 'issue': 'June (6)', 'key': '10.1016/j.toxrep.2021.03.003_bib0075', 'doi-asserted-by': 'crossref', 'first-page': '589', 'DOI': '10.1007/s00011-011-0307-8', 'article-title': 'Anti-inflammatory effects of ivermectin in mouse model of allergic ' 'asthma', 'volume': '60', 'author': 'Yan', 'year': '2011', 'journal-title': 'Inflamm. Res.'}, { 'issue': 'November (11)', 'key': '10.1016/j.toxrep.2021.03.003_bib0080', 'doi-asserted-by': 'crossref', 'first-page': '524', 'DOI': '10.1007/s00011-008-8007-8', 'article-title': 'Ivermectin inhibits LPS-induced production of inflammatory cytokines ' 'and improves LPS-induced survival in mice', 'volume': '57', 'author': 'Zhang', 'year': '2008', 'journal-title': 'Inflamm. Res.'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0085', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.onehlt.2020.100148', 'article-title': 'COVID-19 and the rush for self-medication and self-dosing with ' 'ivermectin: a word of caution', 'volume': '10', 'author': 'Molento', 'year': '2020', 'journal-title': 'One Health'}, { 'issue': '11', 'key': '10.1016/j.toxrep.2021.03.003_bib0090', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0242184', 'article-title': 'Lack of efficacy of standard doses of ivermectin in severe COVID-19 ' 'patients', 'volume': '15', 'author': 'Camprubi', 'year': '2020', 'journal-title': 'PLoS One'}, { 'issue': 'October 13', 'key': '10.1016/j.toxrep.2021.03.003_bib0095', 'article-title': 'Use of ivermectin Is associated with Lower mortality in hospitalized ' 'patients with coronavirus disease 2019: the ICON study', 'author': 'Rajter', 'year': '2020', 'journal-title': 'Chest'}, { 'issue': 'December 2', 'key': '10.1016/j.toxrep.2021.03.003_bib0100', 'first-page': '214', 'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'volume': '103', 'author': 'Ahmed', 'year': '2020', 'journal-title': 'Int. J. Infect. Dis.'}, { 'key': '10.1016/j.toxrep.2021.03.003_bib0105', 'doi-asserted-by': 'crossref', 'first-page': '462', 'DOI': '10.18433/jpps31457', 'article-title': 'Therapeutic potential of ivermectin as add on treatment in COVID 19: a ' 'systematic review and meta-analysis', 'volume': '23', 'author': 'Padhy', 'year': '2020', 'journal-title': 'J. Pharm. Pharm. Sci.'}, { 'issue': '2', 'key': '10.1016/j.toxrep.2021.03.003_bib0110', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0247163', 'article-title': 'Role of ivermectin in the prevention of SARS-CoV-2 infection among ' 'healthcare workers in India: a matched case-control study', 'volume': '16', 'author': 'Behera', 'year': '2021', 'journal-title': 'PLoS One'}], 'container-title': 'Toxicology Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2214750021000445?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2214750021000445?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 4, 29]], 'date-time': '2022-04-29T13:47:28Z', 'timestamp': 1651240048000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2214750021000445'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021]]}, 'references-count': 22, 'alternative-id': ['S2214750021000445'], 'URL': 'http://dx.doi.org/10.1016/j.toxrep.2021.03.003', 'relation': {}, 'ISSN': ['2214-7500'], 'subject': ['Health, Toxicology and Mutagenesis', 'Toxicology'], 'container-title-short': 'Toxicology Reports', 'published': {'date-parts': [[2021]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'RETRACTED: Use of ivermectin in the treatment of Covid-19: A pilot trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Toxicology Reports', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.toxrep.2021.03.003', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 The Authors. Published by Elsevier B.V.', 'name': 'copyright', 'label': 'Copyright'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit